Amphotericin B Polymer Nanoparticles Show Efficacy against Candida Species Biofilms

Abdulghani Alakkad1, Paul Stapleton1, Corinna Schlosser1

  • 1UCL School of Pharmacy, University College London (UCL), 29-39 Brunswick Square, London WC1N 1AX, UK.

Abstract

Insights

Nanoparticulate amphotericin B (AmB) encapsulated in Molecular Envelope Technology (MET) demonstrated significantly enhanced activity against Candida biofilms in vitro. This MET-AmB formulation shows promise for treating drug-refractory fungal infections, including ocular infections.

Area of Science:

  • Mycology
  • Nanotechnology
  • Pharmacology

Background:

  • Chronic Candida infections involve fungal cells embedded in biofilms, which are resistant to antifungal drugs.
  • Candida biofilms are frequently associated with difficult-to-treat ocular fungal infections.

Purpose of the Study:

  • To evaluate the efficacy of nanoparticulate amphotericin B (AmB) using Molecular Envelope Technology (MET) against Candida biofilms.
  • To assess the stability of a MET-AmB ophthalmic formulation.

Main Methods:

  • AmB was encapsulated into MET nanoparticles (N-palmitoyl-N-monomethyl-N,N-dimethyl-N,N,N-trimethyl-6-O-glycolchitosan).
  • The activity of MET-AmB against Candida albicans and Candida glabrata biofilms in vitro was determined.
  • Confocal laser scanning microscopy (CLSM) was used to visualize nanoparticle penetration into biofilms.
  • The stability of MET-AmB eye drops was evaluated at room temperature.

Main Results:

  • MET-AmB exhibited significantly greater potency against C. albicans biofilms (EC50 ~30x lower) and C. glabrata biofilms (EC50 ~10x lower) compared to AmB alone.
  • CLSM confirmed that MET nanoparticles penetrated the biofilm matrix and adhered to fungal cells.
  • MET-AmB showed comparable activity to AmB alone against planktonic C. albicans cells.
  • The MET-AmB eye drop formulation remained stable for at least 28 days at room temperature.

Conclusions:

  • Nanoparticulate AmB delivered via MET demonstrates potent anti-biofilm activity against Candida species.
  • These findings suggest that MET-loaded nanoparticles could be a viable strategy for treating challenging Candida biofilm infections, particularly in ocular settings.